Related Experiment Video
Updated: Apr 30, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better
Chantal Loirat1, Véronique Frémeaux-Bacchi2
11] Department of Pediatric Nephrology, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France [2] Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Atypical hemolytic uremic syndrome (HUS) secondary to anti-factor H autoantibodies has a poor prognosis. The study by Sinha et al. of a large cohort of Indian children makes a substantial contribution to improved management of this form of HUS by showing that standardized titration of anti-factor H autoantibodies is applicable worldwide and that early treatment initiation and guidance of maintenance treatment by autoantibody titer monitoring significantly improve outcomes.
Atypical hemolytic uremic syndrome (HUS) secondary to anti-factor H autoantibodies has a poor prognosis. The study by Sinha et al. of a large cohort of Indian children makes a substantial contribution to improved management of this form of HUS by showing that standardized titration of anti-factor H autoantibodies is applicable worldwide and that early treatment initiation and guidance of maintenance treatment by autoantibody titer monitoring significantly improve outcomes.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Acute Kidney Injury V: Interprofessional Care
Rh Blood Group
Rheumatic Heart Disease III: Medical Management
Venous Thrombosis III: Interprofessional Care

